New Guidelines for Injectable GLP-1 Receptor Agonists Under CGHS: What You Need to Know
Introduction
New comprehensive guidelines now govern the prescription of injectable GLP-1 receptor agonists, including Tirzepatide (Mounjaro) and Semaglutide, under the Central Government Health Scheme (CGHS) and Central Services (Medical Attendance) Rules. These updated directives aim to ensure these high-cost medications are prescribed judiciously, strictly adhering to defined clinical criteria and specialist oversight, making them accessible only to eligible beneficiaries.
Full Article
Tirzepatide (Mounjaro) Joins Restricted Drug List
Following a thorough review of the therapeutic applications of injectable GLP-1 receptor agonists for managing obesity and Type-2 Diabetes Mellitus, the Ministry of Health & Family Welfare has officially approved the inclusion of Injection Tirzepatide, known commercially as Mounjaro, onto the CGHS Online List of Restricted Drugs. This signifies a controlled approach to its availability.
Uniform Prescribing Conditions for GLP-1 Agonists
Both Injection Tirzepatide and Injection Semaglutide will now fall under these newly established, uniform prescribing guidelines for CGHS and CS(MA) Rules. These instructions are effective immediately and are mandatory for all CGHS Wellness Centres and any healthcare organizations that are empaneled with the scheme. This ensures consistency in how these powerful medications are managed.
Eligibility Criteria for GLP-1 Receptor Agonists
To receive a prescription for these injectable GLP-1 receptor agonists, beneficiaries must meet specific clinical conditions. Eligibility is granted if a beneficiary has a Body Mass Index (BMI) of 35 kg/m² or higher. Alternatively, a BMI of 32.5 kg/m² or above, combined with at least one of the following significant medical conditions, also qualifies: Type-2 Diabetes that remains uncontrolled despite treatment with Metformin and at least two other oral anti-diabetic medications, severe Obstructive Sleep Apnoea, established Atherosclerotic Cardiovascular Disease, diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), or Chronic Kidney Disease (CKD).
Exclusions: When These Medicines Cannot Be Prescribed
The guidelines clearly outline specific contraindications where injectable GLP-1 receptor agonists are strictly prohibited. These include beneficiaries with a personal history of pancreatitis, those with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Type-2 (MEN2), individuals who are pregnant or breastfeeding, patients with severe non-proliferative or proliferative diabetic retinopathy, and those suffering from severe gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, or who have a history of metabolic or bariatric surgery.
Mandatory Lifestyle Modifications Pre-Treatment
A crucial prerequisite for initiating therapy with these medications is documented evidence of sustained lifestyle modifications. The treating specialist must certify that the beneficiary has actively engaged in lifestyle changes, including receiving comprehensive dietary counselling and adhering to a supervised physical activity programme. These non-pharmacological interventions must have been consistently followed for a minimum of three months, underscoring the importance of these measures before medical intervention.
Prescription Authority Restricted to Government Specialists
The Office Memorandum imposes stringent controls on who can prescribe these restricted drugs. Prescriptions for injectable GLP-1 receptor agonists can only be issued by an Endocrinologist or an Internal Medicine Specialist working in a Government Hospital. Furthermore, each prescription must receive an endorsement from the concerned Head of Department (HoD). The validity of an approved prescription is set at six months, after which a fresh specialist recommendation and HoD endorsement are required for continuation of treatment.
Structured Monitoring and Follow-Up
Patients undergoing GLP-1 therapy are subject to a structured follow-up schedule to ensure efficacy and safety. Monthly reviews are mandated for the initial three months of treatment, followed by follow-up appointments every three months thereafter. The treating specialist is responsible for meticulously monitoring and documenting key indicators, including weight reduction, overall clinical response, gastrointestinal side effects, any signs of pancreatitis, muscle wasting, and other adverse drug reactions. Continued treatment is contingent upon demonstrated clinical benefit and an acceptable safety profile.
Essential Specialist Certification for Prescriptions
To further enhance accountability and ensure adherence to guidelines, a standardized certification format must accompany every prescription. The specialist is required to accurately record the beneficiary’s current body weight, calculated Body Mass Index (BMI), the presence or absence of any contraindications, and confirm that the mandatory three-month period of lifestyle modification has been successfully completed. If any contraindications are identified, such as a history of pancreatitis or MTC, pregnancy, severe diabetic retinopathy, or specific gastrointestinal disorders, the prescription of GLP-1 therapy must be avoided.
Immediate and Strict Implementation Across CGHS
All Additional Directors of CGHS have been directed to ensure the immediate and strict implementation of these new guidelines across all CGHS Wellness Centres and affiliated empanelled healthcare organizations. Any departure from these prescribed norms will be treated with utmost seriousness. This comprehensive framework is designed to standardize the use of injectable GLP-1 medicines within CGHS, ensuring that these advanced therapies are reserved for beneficiaries who clearly meet the established clinical criteria and are under appropriate specialist care.
Conclusion
The Ministry of Health & Family Welfare’s updated guidelines for injectable GLP-1 receptor agonists represent a significant step towards ensuring the responsible and effective use of these advanced medications under CGHS. By establishing clear eligibility criteria, contraindications, mandatory lifestyle prerequisites, and restricted prescribing authority, the aim is to optimize patient outcomes while managing the utilization of these valuable therapeutic options.
Frequently Asked Questions
What are the new guidelines for injectable GLP-1 receptor agonists under CGHS?
The new guidelines regulate the prescription of injectable GLP-1 receptor agonists, including Tirzepatide (Mounjaro) and Semaglutide, specifying eligibility criteria, contraindications, mandatory lifestyle modifications, specialist supervision, and monitoring requirements.
Which specific injectable GLP-1 receptor agonists are covered by these new guidelines?
The guidelines specifically cover Injection Tirzepatide (Mounjaro) and Injection Semaglutide.
What BMI is required for a beneficiary to be eligible for these medications?
A beneficiary must have a Body Mass Index (BMI) of 35 kg/m² or above, or a BMI of 32.5 kg/m² or above along with at least one specified medical condition.
What are some of the medical conditions that, along with a BMI of 32.5 kg/m² or above, make a beneficiary eligible?
Eligible conditions include uncontrolled Type-2 Diabetes despite treatment, severe Obstructive Sleep Apnoea, Atherosclerotic Cardiovascular Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and Chronic Kidney Disease (CKD).
What are the contraindications for prescribing these GLP-1 receptor agonists?
Contraindications include a history of pancreatitis, personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN2, pregnancy or lactation, severe diabetic retinopathy, and severe gastroesophageal reflux disease (GERD), gastroparesis, or inflammatory bowel disease.
How long must beneficiaries undertake lifestyle modifications before starting treatment?
Beneficiaries must have complied with lifestyle modifications, including dietary counselling and supervised physical activity, for at least three months prior to commencing therapy.
Who is authorized to prescribe these restricted drugs?
Prescriptions can only be issued by an Endocrinologist or an Internal Medicine Specialist working in a Government Hospital.
How long is a prescription for these medications valid?
An approved prescription is valid for six months.
What is the required follow-up schedule for patients on GLP-1 therapy?
Patients require monthly reviews for the first three months, followed by follow-up appointments every three months thereafter.
What key aspects must the treating specialist monitor during follow-up?
The specialist must monitor and document weight reduction, clinical response, gastrointestinal side effects, evidence of pancreatitis, muscle wasting, and any other adverse drug reactions.
